MEYLAN, France, BUBENDORF, Switzerland (November 3rd, 2021) – NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.
Archives News 2021
NH TherAguix announces the enrolment in Boston of the first 2 patients in its clinical trials NANOBRAINMETS and NANOSMART
Meylan (France) and Boston (US), October 1st, 2021 – NH TherAguix announces the enrolment of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis and NANOSMART Phase Ib/II targeting pancreatic cancer and cancerous lung lesions.
NH TherAguix announces the launch of its IPO on the Euronext Growth market in Paris
Grenoble (France), 28 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the launch of its initial public offering with a view to listing its shares on the Euronext Growth market (ISIN code: FR0013105954 – ticket: ALNHT).
NH TherAguix registration document approved by Autorité des Marchés Financiers as part of planned IPO on Euronext Growth Paris
Grenoble (France), 13 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the approval of its registration document by the Autorité des marchés financiers (the “AMF”) under number I.21-048 dated 10 September 2021.
NH TherAguix staff member awarded with a Ph.D. prize
NH TherAguix is pleased to announce that Fabien Boux which joined the Clinical Development Unit as Biomedical Engineer in January, was awarded with the Ph. D. prize 2020 of the Société Française de Résonance Magnétique en Biologie et Médecine (“SFRMBM”).
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients – Grenoble (France), May 31, 2021 – 11:00 pm (CET)